Monthly Archives: October 2017

http://www.lslog.com/merck-hack-causes-gardasil-sales-miss-in-q3-as-drugmaker-borrows-from-cdc/Merck hack causes Gardasil sales miss in Q3 as drugmaker borrows from CDC

Merck hack causes Gardasil sales miss in Q3 as drugmaker borrows from CDC

Merck hack causes Gardasil sales miss in Q3 as drugmaker borrows from CDC Working to recover from a damaging cyberattack, Merck reported that its star HPV vaccine missed sales expectations […]

http://www.lslog.com/roche-pulls-cancer-drug-from-greece-in-fight-over-government-cost-cuts/Roche pulls cancer drug from Greece in fight over government cost cuts

Roche pulls cancer drug from Greece in fight over government cost cuts

Roche pulls cancer drug from Greece in fight over government cost cuts Swiss drugmaker Roche has pulled a cancer drug from the Greek market as it does battle again with […]

http://www.lslog.com/analyst-backing-an-allergan-breakup-is-undeterred-by-doubters-heres-why/Analyst backing an Allergan breakup is undeterred by doubters. Here's why

Analyst backing an Allergan breakup is undeterred by doubters. Here's why

Analyst backing an Allergan breakup is undeterred by doubters. Here’s why RBC Capital Markets analyst Randall Stanicky has fielded some investor pushback to his suggestion that Allergan could be a […]

http://www.lslog.com/keytruda-sales-forecasts-take-a-hit-after-mercks-awkward-eu-app-withdrawal/Keytruda sales forecasts take a hit after Merck's 'awkward' EU app withdrawal

Keytruda sales forecasts take a hit after Merck's 'awkward' EU app withdrawal

Keytruda sales forecasts take a hit after Merck’s ‘awkward’ EU app withdrawal Merck & Co. surprised investors and analysts Friday with news that it had pulled its European application for […]

http://www.lslog.com/insulin-releasing-smart-cells-could-inspire-new-diabetes-treatment/Insulin-releasing ‘smart cells’ could inspire new diabetes treatment

Insulin-releasing ‘smart cells’ could inspire new diabetes treatment

Insulin-releasing ‘smart cells’ could inspire new diabetes treatment Patients with Type 1 diabetes require frequent skin pricks to test their blood and insulin injections to prevent dangerous spikes or drops […]

http://www.lslog.com/aerie-names-allergan-veteran-john-maltman-vp-of-medical-affairs/Aerie names Allergan veteran John Maltman VP of medical affairs

Aerie names Allergan veteran John Maltman VP of medical affairs

Aerie names Allergan veteran John Maltman VP of medical affairs Aerie Pharmaceuticals has appointed John Maltman, Ph.D., as its vice president of medical affairs. Maltman joins the fast-hiring eye disease […]

http://www.lslog.com/under-breakup-pressure-shire-cheers-grumpy-investors-with-q3-earnings-beat/Under breakup pressure, Shire cheers grumpy investors with Q3 earnings beat

Under breakup pressure, Shire cheers grumpy investors with Q3 earnings beat

Under breakup pressure, Shire cheers grumpy investors with Q3 earnings beat Shire shares have taken a beating this year, but they got a boost Friday from third-quarter earnings results investors […]

http://www.lslog.com/abbvie-surprises-street-with-solid-earnings-priority-fda-review-for-endometriosis-med/AbbVie surprises Street with solid earnings, priority FDA review for endometriosis med

AbbVie surprises Street with solid earnings, priority FDA review for endometriosis med

AbbVie surprises Street with solid earnings, priority FDA review for endometriosis med Looming generic competition for AbbVie’s top-selling drug, Humira, threatens the top line while putting extreme pressure on the […]

http://www.lslog.com/freshly-ipod-tocagen-tweaks-brain-cancer-gene-therapy-test/Freshly IPO’d Tocagen tweaks brain cancer gene therapy test

Freshly IPO’d Tocagen tweaks brain cancer gene therapy test

Freshly IPO’d Tocagen tweaks brain cancer gene therapy test Tocagen is moving straight into a phase 3 trial of its gene therapy in cancer and thus needs more patients, but […]

http://www.lslog.com/pdl-goes-public-with-hostile-bid-to-buy-neos/PDL goes public with hostile bid to buy Neos

PDL goes public with hostile bid to buy Neos

PDL goes public with hostile bid to buy Neos PDL BioPharma has gone public with its attempt to buy Neos Therapeutics. The investment group told the world of its desire […]